Early Alzheimer's Diagnostics: Blood Biomarkers and AI Neuro-Analytics Value Chain

The Public Illusion: Do $25,000 Alzheimer’s Drug Developers Capture the Entire Value Chain?

When an aging parent misplaces car keys or repeats the same question three times in an hour, a sudden wave of quiet anxiety grips every family.

Alzheimer’s dementia remains one of the most feared neurodegenerative diseases worldwide, incurring hundreds of thousands of dollars in long-term eldercare costs. With the US FDA approvals of second-generation amyloid-targeting monoclonal antibodies like Leqembi (lecanemab) and Kisunla (donanemab), retail investors reflexively assume: “I must invest in mega-cap biopharma developers producing the drug vials.”

However, an audit of real-world clinical administration pathways and Financial Supervisory Service (DART) regulatory filings reveals a critical gatekeeper industry capturing massive early revenues before a single drug vial is infused.

Three Clinical Realities Behind Alzheimer’s Drug Infusions

• Mandatory Proof of Amyloid Pathology Prior to Treatment: New-generation dementia antibodies costing $25,000 to $30,000 USD (KRW 35M to KRW 40M) annually cannot be prescribed casually. Payers and regulators strictly require 100% objective biomarker proof that toxic oligomeric amyloid-beta plaques exist in the brain.
• Bottlenecks in PET-CT and Lumbar Puncture CSF Tests: Gold-standard Amyloid PET scans cost over $1,500 USD and are restricted to major tertiary medical centers. Lumbar punctures requiring spinal needles trigger severe patient resistance and procedural complications.
• The Explosive Routine Checkup Screening Market: Millions of worried adults in their 50s and 60s are choosing $100 USD simple blood biomarker tests and 5-minute AI EEG/MRI screenings at primary care clinics to detect neurodegenerative risk 10 to 15 years before clinical symptom onset.

💡 The true hyper-growth resides in ‘Non-Invasive Blood Biomarkers’ and ‘AI Neuro-Imaging Gatekeepers’.
The broader the rollout of expensive therapeutic antibodies, the precision diagnostic companies that filter eligible candidates via simple blood draws and AI software harvest recurring revenues across millions of checkup patients.

DART Financial Statement Audit: Drug Developers vs. Essential Diagnostic Enablers

Auditing official regulatory filings from the Financial Supervisory Service (DART) reveals how non-invasive diagnostic enablers are scaling commercial adoption.

Supply Chain Deep Dive: The 4 True Beneficiaries of the Alzheimer’s Diagnostic Wave

1. The Pioneer in Plasma Oligomer Detection — PeopleBio (276730.KQ)

• Multimer Detection System (MDS) Proprietary Moat: Standard blood assays cannot distinguish between harmless monomeric amyloid and neurotoxic aggregated oligomers. PeopleBio’s patented MDS technology selectively amplifies and measures only toxic oligomerized proteins from standard blood draws.
• Health Checkup Market Penetration: Partnered with national diagnostic laboratory networks across Korea, embedding AlzOn blood tests into routine corporate and annual senior executive checkups.

2. AI Brain Volumetrics with US CPT Codes — Vuno (338220.KQ)

• VUNO Med-DeepBrain: Analyzes brain MRI scans in under 1 minute, segmenting over 100 anatomical brain regions and benchmarking hippocampal atrophy percentiles against age-matched normative healthy controls.
• US Reimbursement Catalyst: Successfully secured US CPT Category III reimbursement codes, enabling US clinics to bill Medicare and private insurers whenever DeepBrain is prescribed alongside cognitive evaluations.

3. Geriatric Brain Metabolism Specialty Leader — Samjin Pharm (005500.KS)

• Stable Prescription Cash Engine: Supplies essential neuro-metabolic agents to mild cognitive impairment (MCI) and early-stage dementia outpatients, generating stable annual operating profits.
• Open Innovation Diagnostics Alliances: Partnering with digital health startups developing portable AI electroencephalogram (EEG) helmets to bundle cognitive therapeutics with screening devices.

4. Global Enterprise AI Infrastructure — Lunit (328130.KQ)

• Enterprise Hospital Lock-In: Deployed across 3,000+ hospital radiology departments worldwide, utilizing immense longitudinal clinical imaging data to expand deep-learning algorithms into neurodegenerative biomarker discovery.

🏛️ Valuation Arbitrage Moat: Korean Diagnostic AI vs. Western Bio-Platforms

Global investors pay extreme valuation premiums for Western neuro-diagnostic and imaging SaaS players:

• Global Neuro & Diagnostic Giants: Quanterix (NASDAQ: QTRX, EV/Sales approx. 8x), Eli Lilly (NYSE: LLY, P/E approx. 45x), and Biogen (NASDAQ: BIIB) trade at rich biopharma and diagnostic valuations.
• Korean Non-Invasive AI & Diagnostic Innovators: Korean neuro-AI and blood biomarker companies trade at deeply discounted enterprise valuations, despite possessing FDA clearances, proprietary multimer detection patents, and US reimbursement code activations.
• The Asymmetric Arbitrage: Direct exposure to global Alzheimer’s diagnostic infrastructure at early-stage valuation multiples before worldwide primary-care adoption matures.

🎯 Global Investor Playbook & Ticker Guide

For international portfolio managers and global healthcare investors building Alzheimer’s ecosystem allocations:

1. Brokerage Access & Purchasing Methods:
   • Direct Korean Market Execution: Accessible via Interactive Brokers (IBKR), Charles Schwab, and Fidelity international accounts utilizing standard Korea Exchange (KRX) equity tickers.
   • Tickers for Global Data Feeds:
     • PeopleBio Inc.: Bloomberg 276730:KS / Reuters 276730.KQ
     • Vuno Inc.: Bloomberg 338220:KS / Reuters 338220.KQ
     • Samjin Pharm Co., Ltd.: Bloomberg 005500:KS / Reuters 005500.KS
     • Lunit Inc.: Bloomberg 328130:KS / Reuters 328130.KQ
2. Tax Treaty & Withholding Guidelines:
   • Under the United States-Korea Tax Treaty, foreign dividend withholding tax is capped at 15% (or 16.5% inclusive of local income surtax) when a valid W-8BEN form is filed.
3. Core Monitoring Metrics:
   • US Commercial Health System Integrations: Track quarterly US enterprise hospital software billings for Vuno’s DeepBrain.
   • National Checkup Inclusion Milestones: Monitor regulatory approvals adding plasma amyloid testing to national public health screening vouchers.